What's new in HIV/AIDS. Protective immunity in HIV infection: where do we stand?
In the face of a global epidemic of HIV/AIDS with the majority of individuals living in the developing countries, a protective vaccine seem the foremost goal. As this is not within imminent reach, the other option would be immunotherapy that prolongs the asymptomatic phase of infection. The basis for such a therapy is to understand the correlates of protective immunity against HIV. Here we present the most recent advances regarding selected parts of the immune response towards HIV.
Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, D-80336, Munich, Germany.
R
R
Draenert
F-D
FD
Goebel
D016915:AIDS Vaccines; D000917:Antibody Formation; D000956:Antigens, Viral; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003713:Dendritic Cells; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D016915:AIDS Vaccines; D000956:Antigens, Viral